SORCS3 antisense oligonucleotide and application thereof
SORCS3 antisense oligonucleotide downregulates SORCS3 expression, solves the problem of chemotherapy resistance in GBM patients, improves chemotherapy sensitivity, prolongs survival time, and provides a therapeutic method to improve survival prognosis.
Patent Information
- Application Number
- CN202411401529.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-11-19
AI Technical Summary
Patients with glioblastoma ploidoformis (GBM) have resistance to temozolomide (TMZ) chemotherapy, resulting in a decrease in chemotherapy sensitivity. Due to the existence of the blood-brain barrier, chemotherapy drugs are difficult to reach the affected area, and it is urgent to increase the sensitivity of TMZ chemotherapy. methods to improve survival prognosis.
By designing and applying SORCS3 antisense oligonucleotides, downregulating SORCS3 expression in GBM patients to improve TMZ chemotherapy sensitivity, providing a therapeutic target to enhance glioblastoma's response to TMZ.
By downregulating SORCS3 expression, the chemotherapy sensitivity of GBM patients to TMZ is significantly improved, the survival time is prolonged, and the survival rate of glioma patients is improved.
Smart Images

Figure CN118979040A_ABST
Abstract
Description
Technical Field
[0001] The embodiments of the present invention relate to the field of biomedicine technology, and specifically to a SORCS3 antisense oligonucleotide and an application thereof. Background Art
[0002] SORCS3 belongs to the vacuolar protein sorting 10 protein (VPS10p) receptor family. VPS10p domain receptors are unique sorting receptors that direct intracellular transport between cell surface target proteins, endosomes, Golgi apparatus, and lysosomes in mammalian cells. These proteins have receptor internalization ability. Studies have shown that SORCS3 is closely related to the occurrence and development of glioblastoma, and there is currently no research on the effect of SORCS3 on TMZ chemotherapy sensitivity.
[0003] Temozolomide (TMZ) is an imidazole tetrazine derivative of the alkylating agent dacarbazine and a prodrug of the anticancer drug Temodar, used to treat glioblastoma multiforme (GBM) and astrocytoma. The chemical name of TMZ is 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide. TMZ is stable at pH less than 5, but at pH greater than 7, it is rapidly hydrolyzed to 5-(3-methyltriazine-1-alkyl)imidazole-4-carboxamide (MTIC). However, at least 50% of patients treated with TMZ do not respond to TMZ, which means that TMZ has a certain degree of drug resistance.
[0004] In clinical practice, the vast majority of GBM patients will develop drug resistance after using TMZ chemotherapy, resulting in a decreased survival prognosis. Therefore, finding a way to improve the sensitivity of TMZ chemotherapy is particularly important for improving the survival prognosis of GBM patients in clinical practice. In the treatment of other types of tumors in clinical practice, other drugs are usually combined to improve chemotherapy sensitivity, but due to the special location of GBM onset and the blood-brain barrier, most chemotherapy drugs cannot reach the affected area. TMZ is one of the few chemotherapy drugs that can pass through the blood-brain barrier. There is an urgent need to find more suitable combined targets to improve the sensitivity of TMZ chemotherapy. Summary of the invention
[0005] To this end, an embodiment of the present invention provides a SORCS3 antisense oligonucleotide and application thereof.
[0006] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:
[0007] According to a first aspect of an embodiment of the present invention, the present invention provides a SORCS3 antisense oligonucleotide, the sequence of the SORCS3 antisense oligonucleotide is shown in SEQ ID NO:1.
[0008] According to a second aspect of an embodiment of the present invention, the present invention provides a pharmaceutical composition comprising the SORCS3 antisense oligonucleotide as described above.
[0009] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable excipient.
[0010] According to a third aspect of the embodiments of the present invention, the present invention provides use of the SORCS3 antisense oligonucleotide as described above or the pharmaceutical composition as described above in the preparation of a drug for improving the sensitivity of glioblastoma to chemotherapy drugs.
[0011] Furthermore, the chemotherapy drug is temozolomide.
[0012] Furthermore, the glioblastoma is glioblastoma multiforme or astrocytoma.
[0013] The embodiments of the present invention have the following advantages:
[0014] The present invention mainly improves the chemosensitivity of TMZ by downregulating the expression of SORCS3 in GBM patients, provides a therapeutic target for the treatment of GBM, improves the chemosensitivity of GBM to TMZ, and thus can improve the survival rate of glioma patients and prolong the survival time. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0016] Figure 1 The present invention provides a method for verifying the transfection efficiency of the ASO sequence and the overexpression plasmid in U87MG cells by using PCR technology;
[0017] Figure 2 The present invention provides a method for verifying the SORCS3 overexpression efficiency of U87 MG cells infected with lentivirus by using PCR technology and inverted fluorescence microscopy;
[0018] Figure 3 The present invention provides a CCK-8 experiment to verify that regulating SORCS3 expression affects the changes in cell sensitivity to TMZ chemotherapy;
[0019] Figure 4 The present invention provides a comet assay to verify that regulating SORCS3 expression affects changes in cell chemosensitivity to TMZ. DETAILED DESCRIPTION
[0020] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0021] Example 1
[0022] Cell transfection
[0023] Methods: Three groups of ASO sequences (mASO NC(ome); SORCS3-Homo-ASO-1; SORCS3-Homo-ASO-2) were designed. The ASO sequences are shown in Table 1.
[0024] Table 1
[0025]
[0026] The above ASO sequences were synthesized by Shanghai Jima Gene Co., Ltd. (mASO NC is the blank control group; SORCS3-Homo-ASO-1 is the site 1 acted by the antisense nucleotide; SORCS3-Homo-ASO-2 is the site 2 acted by the antisense nucleotide).
[0027] The artificially synthesized lentivirus-packaged SORCS3 vector was designed, and the vector information is shown in Table 2 below.
[0028] Table 2
[0029] project name Size (bp) Serial Number Species Promoter EFS 232 - - Target gene HumanSORCS3 3669 NM_01498.3 Human
[0030] Cell Grouping:
[0031] U87 cell control group (U87 MG NC); U87 cell transfection with antisense nucleotide SORCS3-Homo-ASO-1 treatment group (U87 MGASO SORCS3-1); U87 cell transfection with antisense nucleotide SORCS3-Homo-ASO-2 treatment group (U87 MGASOSORCS3-2); U87 cell transfection with SORCS3 plasmid overexpression treatment group (U87 MG OE SORCS3); U87 cell infection with lentivirus stably overexpressing SORCS3 treatment group (U87 MG SOE SORCS3).
[0032] Transfection steps:
[0033] 1. Cell plating
[0034] One day before transfection, U87 MG cells of appropriate cell density were seeded in six-well plates and cultured for 24 h to make the cell density at the time of transfection 60%-80%.
[0035] 2. Preparation and transfection of complexes
[0036] 1) Place the ASO transfection reagent at room temperature before use and mix gently before use;
[0037] 2) Add 100 μl serum-free medium and 4 μl Invitrogen Lipofectamine 2000 reagent to a 1.5 ml sterile centrifuge tube. Add 100 μl serum-free medium and 8 μl ASO reagent to another 1.5 ml sterile centrifuge tube. Gently mix the two tubes with a pipette and let stand at room temperature for 5 min.
[0038] 3) Add the ASO-medium mixture dropwise to the Invitrogen Lipofectamine 2000-medium mixture, mix gently with a pipette, let stand at room temperature for 15-20 minutes, and then transfect immediately.
[0039] 3. Transfection process
[0040] 1) While the plate is still, replace the medium in the 24-well plate with 1800 μl of pre-warmed fresh serum-free medium in each well;
[0041] 2) Add 200 μl of transfection mixture to the wells, the final system is 2 ml, and after addition, gently shake the plate to evenly distribute the complex;
[0042] 3) Incubate the cells at 37°C and replace with complete medium after 4-6 hours. Detect SORCS3 mRNA expression after 48 hours and select ASO sequences with higher efficiency for subsequent experiments.
[0043] In addition, we used the above transfection method to construct U87 MG SORCS3 overexpression cells and lentivirus-infected U87 MG SOE SORCS3 overexpression cell lines (to continuously and stably overexpress SORCS3 nucleic acid and protein levels in wild-type U87 cells).
[0044] Note: During the later culture process of the lentivirus-infected U87 MG SOE SORCS3 overexpressing cell line, it is necessary to continue to use complete culture medium containing puromycin at a working concentration of 2μg / mL.
[0045] The transfection efficiency of the constructed SORCS3 antisense nucleotide was detected by using cell culture technology, total RNA extraction and cDNA preparation, and real-time fluorescence quantitative PCR technology. It was shown that compared with wild-type U87 cells, the SORCS3 nucleic acid level of the cells was significantly reduced after ASO treatment, among which site 1 was more efficient than site 2, so site 1 (i.e., SORCS3-Homo-ASO-1) was selected for subsequent experiments. We also tested the transfection efficiency of the SORCS3 overexpression plasmid and the efficiency of lentivirus-infected U87 cells overexpressing SORCS3, showing that compared with wild-type U87 cells, after SORCS3 plasmid transfection treatment, the nucleic acid level of SORCS3 was significantly upregulated, proving that the plasmid overexpression treatment was successful; compared with wild-type U87 cells, after lentivirus infection, the expression of the green fluorescent gene carried by the SORCS3 lentivirus in the cells was clearly observed by inverted fluorescence microscopy, and the expression of SORCS3 was significantly upregulated.
[0046] Example 2
[0047] CCK-8 assay to detect the effect of regulating SORCS3 expression on TMZ chemotherapy sensitivity
[0048] method:
[0049] The above-mentioned U87 cells that had been transfected with SORCS3-Homo-ASO-1 or SORCS3 plasmids and infected with lentivirus and were in logarithmic growth phase were cultured for 10 3 Each well was inoculated in a 96-well plate, and a blank control well was set up, and six sub-wells were set up for each treatment. After 24 hours of culture, it was replaced with 100 μl / well of complete medium containing 500 μM TMZ. After 24 hours, 36 hours, 72 hours, and 96 hours of culture, the complete medium was replaced with a complete medium containing CCK-8 reaction solution. After 3 hours of culture at 37°C and 5% CO2, the absorbance value at 450nm was detected using an enzyme marker. According to the CCK-8 test results for 4 consecutive days, the cell proliferation results were statistically analyzed.
[0050] The blank control group and the treatment group were tested for four consecutive days using the CCK-8 method. The results showed that compared with the wild-type U87 cells, the cell proliferation rate was significantly inhibited after the wild-type U87 cells were treated with plasmids and lentiviruses; compared with the wild-type U87 cells, the cell proliferation rate was significantly inhibited after the U87 cells were treated with oligo antisense nucleotides.
[0051] Example 3
[0052] Comet assay to detect the effect of SORCS3 expression on TMZ chemotherapy sensitivity
[0053] method:
[0054] In the above transfected or overexpressed cells, the cells were treated with 500 μM TMZ for 24 hours and then tested:
[0055] 1) Add 75 μl of comet agarose per well to the comet slide to create a base layer. Use a pipette tip to spread the solution over the wells, making sure to completely cover the wells. Keeping the slide level, transfer the slide to 4°C for 15 minutes;
[0056] 2) Treat the cells with trypsin digestion solution, transfer the cell suspension to a 1.5 ml EP tube, centrifuge at 700 g for 2 min, and discard the supernatant. Wash the cell pellet once with ice-cold PBS, centrifuge, discard the supernatant, and then centrifuge the cells at 1×10 5 Resuspend cells / ml in pre-chilled PBS;
[0057] 3) Mix the cell sample with comet agarose at a ratio of 1 / 10 (v / v), mix thoroughly by pipetting, and immediately transfer 75 μl / well to the top of the comet agarose base layer. Use the pipette tip to gently and carefully spread the suspension, making sure to completely cover the well and not disturb the base layer;
[0058] 4) Keeping the slide level, transfer the slide to 4°C in a dark environment for 15 minutes;
[0059] 5) Carefully transfer the slides to a container of pre-chilled lysis buffer. Soak the slides in the buffer at 4°C in the dark for 30 minutes;
[0060] 6) Carefully aspirate the lysis buffer from the container and replace it with pre-cooled alkaline solution, and soak the slides in a dark environment at 4°C for 30 minutes;
[0061] 7) Aspirate the alkaline solution from the container and replace it with pre-cooled TBE electrophoresis solution. Soak the slides for 5 minutes and repeat once more;
[0062] 8) Keeping the slide level, carefully transfer the slide to the horizontal electrophoresis chamber. Fill the chamber with cold electrophoresis solution until the buffer covers the slide horizontally;
[0063] 9) Apply voltage to the test chamber at a rate of 1v / cm for 30min;
[0064] 10) Keeping the slide level, carefully transfer the slide from the electrophoresis chamber to a clean container of pre-cooled deionized water. Soak the slide for 2 minutes, blot dry, and repeat twice more;
[0065] 11) Discard the deionized water in the container and replace it with cold 70% ethanol and soak for 5 minutes. Keeping the slide horizontal, remove the slide from the 70% ethanol and air dry;
[0066] 12) After the agarose and slides are air-dried, add 100 μl of diluted Vista Green DNA dye to each well and incubate at room temperature for 15 min;
[0067] 13) Observe the slides using a FITC inverted fluorescence microscope.
[0068] We used comet assay to detect the chemotherapy sensitivity of the blank control group and the treatment group (U87 MGASO, U87 MG OE SORCS3), which showed that compared with wild-type U87 cells, the degree of tailing of cells was significantly increased after oligoantisense nucleotide treatment, and the degree of tailing of cells was significantly reduced after SORCS3 plasmid treatment; using fluorescence analysis software for statistics, it was found that the chemotherapy sensitivity of cells was significantly increased after oligoantisense nucleotide treatment.
[0069] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
[0070]
Claims
1. A SORCS3 antisense oligonucleotide, characterized in that The sequence of the SORCS3 antisense oligonucleotide is shown in SEQ ID NO:
1.
2. A pharmaceutical composition comprising the SORCS3 antisense oligonucleotide according to claim 1.
3. The pharmaceutical composition according to claim 2, characterized in that The pharmaceutical composition further includes a pharmaceutically acceptable excipient.
4. Use of the SORCS3 antisense oligonucleotide according to claim 1 or the pharmaceutical composition according to claim 2 in the preparation of a drug for improving the sensitivity of glioblastoma to chemotherapeutic drugs.
5. The use according to claim 4, characterized in that: The chemotherapy drug is temozolomide.
6. The use according to claim 4, characterized in that: The glioblastoma is glioblastoma multiforme or astrocytoma.
